Talaris_large_rgb.png
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
June 14, 2021 16:01 ET | Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris_large_rgb.png
Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
June 03, 2021 07:00 ET | Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 03, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris_large_rgb.png
Talaris Therapeutics Announces Closing of Initial Public Offering
May 11, 2021 16:01 ET | Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris_large_rgb.png
Talaris Therapeutics Announces Pricing of Initial Public Offering
May 06, 2021 21:53 ET | Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard...